@Deep_Brief438 3 weeks ago
PFE isn’t exciting, but cash flow still matters
PFE isn’t exciting, but cash flow still matters
Pfizer has lost its pandemic buzz, but the pipeline and dividend keep it in play. Cycles in healthcare aren’t fast, and opinions change slowly. Value or value trap? Curious to know where others stand, income play for patients or better options elsewhere?
@Hudsonriley 3 weeks ago
More of a patient income play to me. It's not exciting, but not a trap either
